慢性气道疾病是一组累及气道、肺组织的慢性非传染性疾病，主要包括支气管哮喘、慢性阻塞性肺疾病、特发性肺纤维化、支气管扩张等。黄芪甲苷可通过减轻气道炎性损伤、调节免疫功能、减轻氧化损伤、延缓气道重塑、调控细胞凋亡、促进血管新生治疗慢性气道疾病。总结了黄芪甲苷治疗慢性气道疾病的药理作用研究进展，为黄芪甲苷的作用靶点挖掘和新药开发提供方向。

Chronic airway diseases are a group of chronic non-communicable conditions affecting the airways and lung tissues, primarily including bronchial asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and bronchiectasis. Astragaloside IV can treat chronic airway diseases by reducing airway inflammatory damage, regulating immune function, alleviating oxidative damage, delaying airway remodeling, regulating cell apoptosis, and promoting angiogenesis. This article summarizes the research progress on the pharmacological effects of Astragaloside IV in treatment of chronic airway diseases, providing direction for the exploration of the target of Astragaloside IV and the development of new drugs.

R286.4

德阳市科技计划项目（2025SYCX116）